April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Clinical course of Vogt-Koyanagi-Harada disease in Brazilian patients
Author Affiliations & Notes
  • Joyce H Yamamoto
    Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
  • Viviane Mayumi Sakata
    Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
  • Carlos E Hirata
    Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
  • Maria Lucia C Marin
    Laboratory of Immunology, Heart Institute, Universidade de Sao Paulo, Faculdade de Medicina, Sao Paulo, Brazil
  • Helcio Rodrigues
    Laboratory of Immunology, Heart Institute, Universidade de Sao Paulo, Faculdade de Medicina, Sao Paulo, Brazil
  • Walter Y Takahashi
    Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
  • Rogerio A Costa
    DIvision of Macular, Centro Brasileiro de Ciências Visuais, Belo Horizonte, Brazil
    Ophthalmology, Universidade de São Paulo Faculdade de Medicina, Ribeirão Preto, Brazil
  • Footnotes
    Commercial Relationships Joyce Yamamoto, None; Viviane Sakata, None; Carlos Hirata, None; Maria Lucia Marin, None; Helcio Rodrigues, None; Walter Takahashi, None; Rogerio Costa, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5799. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joyce H Yamamoto, Viviane Mayumi Sakata, Carlos E Hirata, Maria Lucia C Marin, Helcio Rodrigues, Walter Y Takahashi, Rogerio A Costa; Clinical course of Vogt-Koyanagi-Harada disease in Brazilian patients. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5799.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Purpose: To describe the clinical course of patients with Vogt-Koyanagi-Harada disease (VKHD) treated with a standard high-dose systemic corticosteroid between 1997 and 2013.

 
Methods
 

This retrospective and longitudinal study included patients with VKHD (Revised Diagnostic Criteria) with a minimum one-year follow-up and early (less than 30 days from disease onset) standard high-dose systemic corticosteroid followed by slow tapering of oral corticosteroids over a minimum of 6 months. Therapy was adjusted according to clinical and fluorescein angiography (FA) evidence of disease activity. Demographic data, disease category, recurrence or chronic inflammation, fundus based severity and ocular complications were noted. Initial and final visual acuity was included. HLA-DRB1 loci were typed by a PCR-SSO-Luminex method. The study protocol followed the statements of the Declaration of Helsinki and was approved by local Institutional Review Board.

 
Results
 

29 patients were included. Their clinical characteristics are described in the Table. Concerning the course of the disease, 8 patients (28%) had no clinical and/or FA disease recurrence (group 1) and were all characterized by mild fundus, no ocular complications and final vision ≥0.8. Twenty one patients (72%) had recurrent or chronic inflammation (group 2), among which 10 patients (48%) had subretinal fibrosis (group 2b) and 11 patients (52%) did not (group 2a). Parameters, such as age, interval to treatment, duration of systemic corticosteroid treatment, were similar between groups 1,2a and 2b. Nevertheless, systemic immunosuppressant and ocular complications were more frequent in group 2a/b (p<0.001)). HLA-DRB1*04 allele group frequencies analysis in patients and controls showed a higher frequency in VKH group (p=0.0008; OR 4.8; IC 95%1.95-11.80). A highly significant increase of the HLA-DRB1* 0405 was disclosed upon HLA-DR4 allele typing (p<0.0001; OR 11.38; IC 95% 3.95-32.81). HLA-DRB1*0405 distribution in each clinical group can be observed at Table. Despite the small number of individuals analyzed, this data suggest that HLA-DRB1*0405 may be associated to disease severity.

 
Conclusions
 

VKHD may have different clinical course independently of therapy and known prognostic factors. HLA-DRB1*0405 might be associated to disease severity. Further understanding of the spectrum of VKHD is demanded.

  
Keywords: 746 uveitis-clinical/animal model • 462 clinical (human) or epidemiologic studies: outcomes/complications • 539 genetics  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×